By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

AmpliPhi Biosciences (Formerly known as Targeted Genetics) 

4870 Sadler Road
Suite 300
Glen Allen  Virginia  23060  U.S.A.
Phone: 804-205-5069 Fax: 206-223-0288


SEARCH JOBS
AmpliPhi Biosciences is a biopharmaceutical company focused on the development of an internally generated pipeline of naturally occurring viruses called bacteriophage (phage) for the treatment of bacterial infection. Phage-based therapy provides a unique and proven approach to treating a wide variety of bacterial infections and in particular, drug-resistant strains of bacteria that are commonly found in the hospital setting. We have built a drug development and manufacturing platform designed to allow rapid development and production of multiple phage-based therapies. Our plan and success relies on our ability to identify and develop selected phage to eradicate targeted bacterial infections across a wide range of bacterial disease. Initially our phage discovery and development platform will focus efforts in acute and chronic lung, sinus and gastrointestinal (GI) infections.

AmpliPhi maintains operations in Richmond, Virginia in the United States, in Colworth Science Park, near London in the United Kingdom, and outside Sydney, NSW, Australia.


Key Statistics


Email: n/a
Ownership: Public

Web Site: AmpliPhi Bio
Employees:
Symbol: APHB
 





Collaborations

Collateral Therapeutics Inc.  Vector-licensing agreement for the potential treatment of congestive heart failure.





Company News
AmpliPhi Bio (APHB) Provides Update On Phase I Trial In Chronic Rhinosinusitis Patients 9/20/2016 11:04:05 AM
AmpliPhi Bio (APHB) To Participate In Upcoming Conferences 9/13/2016 12:15:03 PM
AmpliPhi Bio (APHB) Announces Topline Results From Its Phase I Phage Therapy Trial Conducted In The United States 9/13/2016 10:39:20 AM
AmpliPhi Bio (APHB) To Participate In Upcoming Conferences 9/13/2016 10:22:20 AM
AmpliPhi Bio (APHB)’ Bacteriophage Cocktail Shown To Prevent C. difficile Biofilm Formation And Reduce Colonization 9/12/2016 9:44:44 AM
AmpliPhi Bio (APHB) Reports Second Quarter 2016 Financial Results And Provides Corporate Update 8/16/2016 8:07:20 AM
AmpliPhi Bio (APHB) Confirms Clinical Trial Progress And Announces Upcoming Conference Call To Provide Corporate Update And Discuss Second Quarter 2016 Financial Results On August 15, 2016 8/9/2016 11:16:52 AM
AmpliPhi Bio (APHB) Granted Japanese Patent Covering The Use Of Phage Therapy To Resensitize Pseudomonas Aeruginosa Infections To Antibiotics 8/4/2016 12:01:15 PM
AmpliPhi Bio (APHB) Completes Enrollment Of Its Investigational Phage Therapy Trial Targeting Staphylococcus Aureus 8/3/2016 11:12:14 AM
AmpliPhi Bio (APHB) To Be Granted European Patent Covering The Use Of Phage Therapy To Resensitize Bacterial Infections To Antibiotics 6/2/2016 10:48:08 AM
12345678910...
//-->